William Blair & Company’s Avadel Pharmaceuticals AVDL Stock Holding History

William Blair & Company’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,250	Closed	-$68K	–	1853
2020 Q4	$68K	Buy	10,250 +250	+3%	+$1.56K	﹤0.01%	1589
2020 Q3	$50K	Sell	10,000 -2,500	-20%	-$18.2K	﹤0.01%	1509
2020 Q2	$101K	Sell	12,500 -4,500	-26%	-$39.7K	﹤0.01%	1369
2020 Q1	$135K	Buy	+17,000	New	+$131K	﹤0.01%	1262
2017 Q3	–	Sell	-180,174	Closed	-$1.99M	–	1369
2017 Q2	$1.99M	Buy	180,174 +10,150	+6%	+$102K	0.01%	570
2017 Q1	$1.81M	Buy	+170,024	New	+$1.7M	0.01%	567

Other funds holding AVDL

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ACM

Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

William Blair & Company's AVDL Position: Q1 2021 in Review

William Blair & Company sold out of Avadel Pharmaceuticals (AVDL) in Q1 2021, closing a stake of 10,250 shares — an estimated $68K sold.

William Blair & Company first reported a position in AVDL in Q1 2017 and held it in 6 quarters. The position peaked at $1.99M in Q2 2017. 76 funds tracked by Wall St. Rank hold AVDL as of Q1 2021.

William Blair & Company reported no remaining Avadel Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
William Blair & Company sold 10,250 Avadel Pharmaceuticals shares in Q1 2021, an estimated $68K.
William Blair & Company first reported a position in Avadel Pharmaceuticals in Q1 2017 and held it in 6 quarters.
William Blair & Company's Avadel Pharmaceuticals position peaked at $1.99M in Q2 2017.
76 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2021.

Based on William Blair & Company's 13F filing for Q1 2021, filed 13 May 2021.